Merck Announces Changes in Operating Model for Healthcare Business Sector

Chris Round will leading the US and Canada Healthcare business

19-May-2021 - Germany

Merck announced changes in its operating model for the Healthcare business sector. Chris Round will become President of EMD Serono leading the North America Healthcare business; Andrew Paterson will assume the position of Chief Marketing Officer; and recruitment is ongoing for the position of Head of China & International.

“Our redesigned Healthcare organization creates dedicated leadership for our strategic priorities with a focus on growth,” said Peter Guenter, Member of the Executive Board of Merck, and CEO Healthcare. “Our clear intent is to bring meaningful value to more patients with our current and future portfolio.”

Given the priority of North America as a driver of future growth for Merck’s Healthcare business sector, dedicated leadership in this key market is essential. To this end, Chris Round will assume the role of President of EMD Serono, leading the US and Canada Healthcare business. Round has been with the organization since 2017, previously serving as Head of International and Core Franchises, and Head of EMEA. Round brings 25 years of global pharmaceutical experience to this position, including 20 years at MSD. He will be based in Rockland, Massachusetts, USA.

The ongoing launches of BAVENCIO^® (avelumab), MAVENCLAD^® (cladribine) tablets and TEPMETKO^® (tepotinib) are critical elements of the business sector’s growth strategy. Global launch excellence for existing and future therapies will be led by Andrew Paterson, who will assume the role of Chief Marketing Officer for Healthcare. Paterson will lead Merck’s Speciality Franchises including Oncology, Neurology & Immunology and Fertility. In addition, Paterson will lead Global Market Access & Pricing and Global Strategic Insights. Paterson brings nearly 30 years of leadership experience in the biopharmaceutical industry to this appointment. He previously led both North America and the Global Innovative Medicine Franchises. Paterson will also be based in Rockland.

The executive role, Head of China & International, will lead China and Japan as well as the regions Europe, Latin America, Asia-Pacific and Middle East, Africa and Russia, and the franchise of Cardiovascular Metabolism & Endocrinology (CM&E). Recruitment for this position is ongoing.

https://www.bionity.com/en/news/1171142/merck-announces-changes-in-operating-model-for-healthcare-business-sector.html